Equities

Linical Co Ltd

2183:TYO

Linical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)440.00
  • Today's Change-1.00 / -0.23%
  • Shares traded15.00k
  • 1 Year change-42.41%
  • Beta0.6899
Data delayed at least 20 minutes, as of Jul 23 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.

  • Revenue in JPY (TTM)12.31bn
  • Net income in JPY338.27m
  • Incorporated2005
  • Employees662.00
  • Location
    Linical Co Ltd10F, Shin-Osaka Brick Bldg1-6-1, MiyaharaYodogawa-kuOSAKA-SHI 532-0003JapanJPN
  • Phone+81 661502478
  • Fax+81 661502675
  • Websitehttps://www.linical.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cyfuse Biomedical KK64.79m-645.40m5.97bn21.00--1.94--92.12-82.27-82.278.26378.390.01530.520213.803,085,095.00-15.19---17.68--61.81---996.19--6.39-81.610.2126---83.68---24.32------
Veritas In Silico Inc-100.00bn-100.00bn6.05bn15.00--2.57----------363.52------------------------40.94--0.00--101.54--123.38------
Kringle Pharma Inc77.93m-904.81m6.46bn13.00--2.66--82.91-159.92-159.9213.58356.640.027--2.805,994,308.00-31.29-19.00-33.20-20.23-----1,161.12-156.5112.85--0.00---82.33---157.41------
Chiome Bioscience Inc642.70m-1.30bn6.99bn51.00--5.54--10.88-25.56-25.5612.6022.390.33484.278.9612,602,040.00-67.53-50.50-88.83-57.3855.9657.53-201.70-224.743.46-629.880.2009--8.1926.241.84------
Carna Biosciences, Inc.1.58bn-1.03bn7.39bn67.00--1.99--4.67-60.32-60.3292.24205.190.35741.2412.6323,578,990.00-23.36-14.45-25.26-16.9589.0390.59-65.36-35.4213.18--0.0326--17.2416.5914.57---27.69--
TMS Co Ltd0.00-1.06bn9.27bn14.00--2.89-----27.96-27.960.0079.720.00----0.00-30.42---31.24----------29.35-1,052.640.00-------11.51------
OncoTherapy Science, Inc.610.12m-1.29bn10.51bn54.00--24.62--17.23-6.09-6.092.871.620.5139.087.6911,298,480.00-108.31-55.67-182.73-63.82-29.13-1.49-211.13-247.472.07-189.930.232---46.2416.81-15.15---48.33--
Linical Co Ltd12.31bn338.27m10.91bn662.0029.451.2112.740.886514.9814.98544.92364.600.6837--3.5918,591,950.001.884.013.156.3330.7030.992.755.48----0.267250.81-1.671.70-66.32-9.86-10.184.56
AnGes Inc249.94m-6.35bn11.16bn145.00--0.3777--44.64-32.62-32.621.29124.450.00770.08624.771,723,752.00-19.47-28.50-23.06-33.1439.8539.42-2,540.59-6,726.820.9124--0.0139--128.13-24.1749.45--12.11--
Medinet Co Ltd711.82m-1.40bn11.54bn98.00--2.07--16.21-6.00-6.003.0321.730.12411.343.787,263,510.00-24.31-21.05-25.48-22.4715.2528.75-196.06-135.4020.08--0.00--4.40-7.90-14.66---17.67--
Tsubota Laboratory Inc673.53m-641.32m11.79bn7.00--8.62--17.51-25.15-25.1526.4253.450.27112.0437.7496,218,860.00-25.82---36.41--3.17---95.22--2.31-489.860.0788---29.45---811.14------
Noile-Immune Biotech Inc311.30m-975.80m11.86bn28.00--2.22--38.11-22.56-22.567.19123.550.06580.1395.0711,118,000.00-20.62---21.29--99.55---313.45--52.74-805.650.00---49.37---192.28------
3-D Matrix Ltd4.59bn-255.51m12.40bn108.00--32.58--2.70-3.56-3.5662.614.330.78360.51345.16---4.36-42.10-5.76-55.6067.2653.95-5.57-96.031.91--0.922--98.3069.4189.55---30.34--
Nano Mrna Co Ltd135.51m-780.00m13.84bn18.00--4.03--102.15-11.10-11.101.9348.610.02559.029.667,528,222.00-14.37-24.16-15.59-25.1781.8884.69-575.61-600.709.17--0.2448---32.98-22.8840.50------
PRISM BioLab Co Ltd-100.00bn-100.00bn15.80bn22.00--6.84----------65.39----------------------------0.00---79.63---822.18------
Data as of Jul 23 2024. Currency figures normalised to Linical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

3.48%Per cent of shares held by top holders
HolderShares% Held
Sawakami Asset Management, Inc.as of 30 Apr 2024348.70k1.41%
Nomura Asset Management Co., Ltd.as of 31 May 2024143.90k0.58%
Dimensional Fund Advisors LPas of 04 Jul 202494.30k0.38%
Norges Bank Investment Managementas of 31 Dec 202368.50k0.28%
Nikko Asset Management Co., Ltd.as of 05 Jul 202466.80k0.27%
Daiwa Asset Management Co. Ltd.as of 28 Jun 202462.80k0.25%
Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jul 202428.10k0.11%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 04 Jul 202419.40k0.08%
BlackRock Japan Co. Ltd.as of 04 Jul 202418.10k0.07%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 19 Feb 202410.90k0.04%
More ▼
Data from 31 Dec 2023 - 18 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.